Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 265.85% from the company’s previous close.

Separately, EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th.

Enlivex Therapeutics Trading Up 3.8 %

ENLV opened at $1.64 on Friday. The firm’s 50 day moving average is $1.34 and its 200-day moving average is $1.77. Enlivex Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Friday, August 30th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. On average, sell-side analysts anticipate that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned approximately 0.12% of Enlivex Therapeutics as of its most recent filing with the Securities & Exchange Commission. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.